Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
Podden och tillhörande omslagsbild på den här sidan tillhör BMJ Group. Innehållet i podden är skapat av BMJ Group och inte av, eller tillsammans med, Poddtoppen.
